TIGIT Therapies Digital Summit

Memo

The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT's diverse function in multiple cell types has made it a lucrative immunotherapy candidate, with an increasing number of candidates being investigated in pre-clinical and clinical settings. As evidence of TIGIT's clinical potential builds, the TIGIT Therapies Digital Summit brings you a comprehensive insight, from the fundamental biology to early clinical development, and the next wave of ICI. Hear from leaders in TIGIT development from Merck, Compugen, iTeos Therapeutics, Agenus and more! Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. Following the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications, a great deal of momentum has built in this competitive space. However, core challenges must still be addressed by the community, such as: Investigating the TIGIT pathway, ligands, and modes of actionOptimizing biomarker strategy to identify optimal patient populations and indicationsRationalizing combination strategy to leverage the TIGIT mechanism for maximum therapeutic benefit. The TIGIT Therapies Digital Summit will gather all the greatest minds in TIGIT research under one virtual roof. Gain access to 1:1 time with leaders in TIGIT research, and take away tangible learnings. In such a fast-paced industry, this is a unique opportunity to provide an overview of the 'knowns and unknowns' in the field, and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. At a time when we are more isolated than ever, this meeting will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. URLs:Tickets: https://go.evvnt.com/666284-2?pid=5569Brochure: https://go.evvnt.com/666284-3?pid=5569 Prices:Digital Conference Ticket - 1st Release (Book by August 21): USD 1300.0,Digital Conference Ticket - 2nd Release (Book by September 18): USD 1400.0,Digital Conference Ticket - 3 Release (Book by October 9): USD 1500.0,Digital Conference Ticket - Final Release: USD 1600.0 Speakers: Dhan Chand, Scientific Director, Head of Drug Discovery, Agenus Bio, Jane Grogan, Chief Scientific Officer, Arsenal Bio, Vijay Kuchroo, Director Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Eran Ophir, Vice President Research and Drug Discovery, Compugen Inc., Yvonne McGrath, Vice President Research and Development, iTeos Therapeutics, Ecaterina Dumbrava, Assistant Professor, MD Anderson Cancer Center, Jane Healy, Senior Principal, Scientist Merck, Taylor Schreiber, CEO, Shattuck Labs, Michael Lim, Chair of Neurosurgery, Stanford University, Hassane Zarour, Professor of Medicine, Immunology ad Dermatology, UPMC Hillman Cancer Center, Walter Fielder, Principal Investigator, University Medical Center Hamburg- Eppendorf, Navneet Bhogal, Principal Research Analyst, Beacon Targeted Therapeutics Date and Time: On Monday October 26, 2020 at 9:00 am (ends Tuesday October 27, 2020 at 1:00 pm)